These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Treatment of Raynaud's phenomenon. García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Pardo-Santos R; Levy R; Maldonado CG; Chávez GP; Cervera R Autoimmun Rev; 2008 Oct; 8(1):62-8. PubMed ID: 18692160 [TBL] [Abstract][Full Text] [Related]
5. [Recent advances in Raynaud's syndrome]. Klein-Weigel P Dtsch Med Wochenschr; 2012 Mar; 137(13):622-4. PubMed ID: 22434167 [No Abstract] [Full Text] [Related]
6. [An update on the management of Raynaud's phenomenon]. Rodríguez-García JL An Med Interna; 1991 Oct; 8(10):513-20. PubMed ID: 1751694 [TBL] [Abstract][Full Text] [Related]
7. Raynaud's phenomenon: Current concepts. Stringer T; Femia AN Clin Dermatol; 2018; 36(4):498-507. PubMed ID: 30047433 [TBL] [Abstract][Full Text] [Related]
10. Treatment of patients with secondary Raynaud's syndrome. Ehrly AM Acta Chir Scand Suppl; 1976; 465():92-5. PubMed ID: 1069443 [TBL] [Abstract][Full Text] [Related]
11. Assessment of platelet function in patients with Raynaud's syndrome. Hutton RA; Mikhailidis DP; Bernstein RM; Jeremy JY; Hughes GR; Dandona P J Clin Pathol; 1984 Feb; 37(2):182-7. PubMed ID: 6229551 [TBL] [Abstract][Full Text] [Related]
12. Prostaglandin I2 and E1 and red cell deformability in raynaud's phenomenon and systemic sclerosis. Gaylarde PM Br Med J (Clin Res Ed); 1981 Dec; 283(6306):1608-9. PubMed ID: 6796187 [No Abstract] [Full Text] [Related]